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Case 1 : A 73-year-old man presented with a serum prostate speciﬁc antigen (PSA) level of 30.2 ng/ml,
and was diagnosed with prostate cancer (cT3aN0M1, stageD2), for which hormonal therapy (maximal
androgen blockade : MAB) was commenced. Nine months later he developed back pain, and osteolytic
bone lesions progressed despite a stable, low PSA level (0.087 ng/ml). He was diagnosed with multiple
myeloma on the basis of positive M protein on immunoelectrophoresis. MP combination therapy
(melphalan and prednisolone) was commenced, but the patient died of multiple myeloma 33 months later.
Case 2 : A 70-year-old man was diagnosed with prostate cancer (PSA 19 ng/ml) at another hospital 5 years
ago, and underwent hormonal therapy (luteinizing hormone-releasing hormone (LHRH) agonist only). He
was referred to our hospital and underwent bicalutamide＋MAB combination therapy due to a raised PSA
level (58 ng/ml) and multiple bone metastases. His PSA level dropped to around 20 ng/ml, but 2 years
later he developed back pain, and bone metastases with osteolytic change were seen in the skull, ribs, and
limbs. Needle aspiration biopsy of a ﬁst-sized soft tissue mass in the chest wall showed multiple myeloma.
Although chemotherapy with melphalan was commenced, the patient died of multiple myeloma 8 months
after its diagnosis. Both these cases exhibited rapidly progressing bone lesions, regardless of an absence of
any large ﬂuctuations in serum PSA levels, during hormonal therapy for prostate cancer. Further
investigations yielded the diagnosis of multiple myeloma. If progression of bone lesions does not match the
status of prostate cancer as surmised from the serum PSA level, we should consider the possibility of multiple
myeloma, and biopsy of one of the bone lesions.
(Hinyokika Kiyo 58 : 243-247, 2012)







患者 1 : 73歳，男性
主訴 : 背部痛
既往歴 : 高血圧
現病歴 : 2007年 3月血清 PSA 高値を主訴に当科受
診．PSA 38.7 ng/ml にて前立腺生検を施行し，前立
腺癌 (Gleason score 4＋4＝8) を検出した．骨シンチグ
ラフィーにて Th5 および肋骨に高集積あり (EOD1)
(Fig. 1A），前立腺癌 cT3aN0M1 (OSS) (stage D2) の
* 現 : 埼玉医科大学総合医療センター泌尿器科
診断で酢酸リュープロレリンおよびビカルタミドによ
る MAB 療法を開始した．なお初診時の総蛋白 (TP)
は 7.7 g/dl と高値であった．PSA は順調に低下し，
10月には PSA 0.087 ng/ml となったが，12月初旬より
高度の背部痛が出現したため，当科入院となった．
検査所見 1
血液生化学所見 : 白血球数 7,800/μ l，赤血球数
323×104/μ l，血小板 24×104/μ l，TP 9.0 g/dl，Alb
4.0 g/dl，BUN 46 mg/dl，Cr 4.92 mg/dl，血清カルシ














Fig. 1. A : Bone scintigraphy revealed high accumulations in Th5 and costae (March,
2007). B : Bone scintigraphy revealed multiple high accumulations in thoracic
and lumber vertebra (December, 2007).
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Fig. 2. Computerised tomography revealed a soft
tissue mass (white arrow) and osteolytic
change with punched out lesions in thoracic
spine and costae (black arrows).
検査所見 2
免疫電気泳動 : M蛋白陽性．
免疫検査所見 : IgG 2, 954 mg/dl（正常値 870∼
1,700 mg/dl），IgA 32 mg/dl（正常値 110∼410 mg/dl），











患者 2 : 70歳，男性
主訴 : 左胸部腫瘤
既往歴 : 左鼠経ヘルニア，糖尿病
現病歴 : 2001年 5月前医において PSA 19 ng/ml に
て前立腺生検が施行され，前立腺癌 stage B2 の診断に
て酢酸リュープロレリン単独のホルモン療法が開始さ
れたが，通院は不規則で治療が不十分な状態であっ
た．前医通院困難にて2006年 5 月当科初診．PSA 58
ng/ml，骨シンチグラフィーにて Th6，L3 および仙腸
関節に散発性の高集積を認めた (EOD2) (Fig. 4A）．
なお初診時の TP は 8.0 g/dl と高値であった．酢酸
リュープロレリンおよびビカルタミドによる MAB 療






血液生化学 : 白血球数 4,800/μl，赤血球数 384×
104/μl，血小板数 17.7×104/μl，TP 8.4 g/dl，Alb 4.0
g/dl，BUN 9.2 mg/dl，Cr 0.59 mg/dl．
腫瘍マーカー : PSA 34. 6 ng/ml，Neuron-speciﬁc
enolase (NSE) 9.0 ng/ml（正常値 12.0 ng/ml 以下）．
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Fig. 4. A : Bone scintigraphy revealed high accumulations in Th6 and L3 (May, 2006).
B : Bone scintigraphy revealed multiple new high accumulations in the cranium,
scapula, humerus and tibia (April, 2008).
下腿に新たな高集積の多発が認められた (EOD3)
(Fig. 4B）．
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Fig. 5. Computerised tomography revealed soft
tissue mass in the chest wall.




Fig. 6. Pathological examination of soft tissue mass in the chest wall revealed multiple myeloma (HE stain, A : ×
40, B : ×200).
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Fig. 7. Clinical events in case 2.
(Fig. 7）．
考 察




泌分化 (NED : neuroendocrine differentiation) である1)．
NED のマーカーとして代表的なものに，NSE，












HRPC となった段階で組織内・血中とも PSA がまっ
たく検出されなかった報告もある3)．この現象につい
ての詳細な機序は明らかではないが，内分泌抵抗性の
















た，多発性骨髄腫はreceptor activator of nuclear factor κ
B ligand (RANKL) 産生を介して破骨前駆細胞の活性
化に関わっており，前立腺癌の骨転移プロセスに影響
を及ぼす可能性が考えられる6)．Retrospective に考え
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